MOPETT, 2012 trial summary    PDF trial summary

A randomised clinical trial investigating the effect of half-dose t-PA versus no fibrinolysis in patients presenting with moderate PE


Studied treatment half-dose thrombolysis
half-dose thrombolysis (for those >50 kg, 10 mg in one minute followed by 40 mg in two hours; for those <50 kg, 0.5 mg/kg total dose: 10 mg in one minute followed by the remainder in two hours) and concomitant anticoagulation with around a 20% to 30% reduced dose of enoxaparin or heparin
Control treatment standard regimen of anticoagulants alone

Patients patients presenting with moderate PE
Group sizes-9 / -9

Blindness open Inclusion period
Follow-up duration 28 months Centers single center
Lost to FU geographical localisation
Primary endpoint Pulmonary hypertension Design Parallel groups
Systolic blood pressure
Diastolic blood pressure
delay from onset
diagnostic test

EndpointX1N1X0N0TE95% CI All cause death - -9 - -9 no data minor bleeding - -9 - -9 no data recurrence of pulmonary embolism - -9 - -9 no data major bleeding - -9 - -9 no data0,22,01,0

Registering number (see trial on
Code Name


All trials of half-dose t-PA

Appears in following systematic reviews: